Market Cap 819.27M
Revenue (ttm) 0.00
Net Income (ttm) -74.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 868,500
Avg Vol 1,347,586
Day's Range N/A - N/A
Shares Out 90.83M
Stochastic %K 62%
Beta 0.04
Analysts Strong Sell
Price Target $14.00

Company Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 206 4507
Address:
275 Shoreline Drive, Suite 500, Redwood City, United States
oaksapollo
oaksapollo Oct. 24 at 1:54 PM
$RZLT open interest on Nov $10 calls is huge, no doubt that’s where we’re headed in the near term.
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 24 at 3:15 AM
$RZLT i was thinking through who may be the most likely acquirer. my guess based on recent bod and mgmt team additions is that it's $RARE. sunil karnawat joined in august 2025 as cco. prior to this, he was an exec at ultragenyx from 2017-2024. erik harris joined the bod in march 2025 and currently serves as cco of ultragenyx. the question i have is how they would structure this deal. ultragenyx doesn't have a lot of cash, but quite a bit of debt. thus, they likely wouldn't be able to do an all-cash deal funded with additional debt. so it would need to likely be cash + stock + contingent payments. i would much rather it be $LLY $NVO $TAK but signs don't point to any of these companies.
1 · Reply
oaksapollo
oaksapollo Oct. 23 at 4:33 PM
$RZLT man what the hell? The stock is now lower than it was prior to the 8K, all gains from yesterday given back and then some. Someone large must be getting out. A bit concerning...
2 · Reply
outlawinvestor1
outlawinvestor1 Oct. 23 at 3:55 PM
$RZLT adding!!!
0 · Reply
marti837
marti837 Oct. 23 at 2:36 PM
$RZLT add
0 · Reply
Zyntax
Zyntax Oct. 23 at 5:20 AM
$RZLT Here’s what I probably could happen if BO price has not yet been set, but I don’t know of course anout the timeframe either. 1. Share price climbs up till X point 2. Outstanding data comes out, we shoot +100% of whatever share price is 3. BO news comes out and we shoot another +100% This would be nice to happen: 1. Share price climbs to $12 before topline data 2. After topline data we are at $24 3. BO news comes out and we are at $48 Not a financial advice. Of course there will be those sellers who sell once topline data comes out and share price jumps
1 · Reply
outlawinvestor1
outlawinvestor1 Oct. 22 at 8:51 PM
$RZLT while previously announced on sept 2 in a pr, the company made the official change to the tumor hi trial record in ct (same day as sec filing - 10/17), further buttoning up loose ends before... 😉 https://clinicaltrials.gov/study/NCT06881992?spons=Rezolute&tab=history&a=5&b=6&compareMode=sideBySide#version-content-panel
0 · Reply
Monty3030
Monty3030 Oct. 22 at 7:56 PM
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Oct. 22 at 7:51 PM
$RZLT Lovely
0 · Reply
SybilDorsett
SybilDorsett Oct. 22 at 7:22 PM
$RZLT Can you imagine where this will go if news comes out AH?
1 · Reply
Latest News on RZLT
Rezolute to Participate in Upcoming Investor Conferences

Oct 15, 2025, 8:00 AM EDT - 10 days ago

Rezolute to Participate in Upcoming Investor Conferences


Rezolute: RZ402 Could Be A Surprise Candidate In The Making

May 1, 2025, 3:57 AM EDT - 6 months ago

Rezolute: RZ402 Could Be A Surprise Candidate In The Making


Rezolute, Inc. Announces Closing of Underwritten Offering

Apr 25, 2025, 4:30 PM EDT - 6 months ago

Rezolute, Inc. Announces Closing of Underwritten Offering


Rezolute: Late-Stage Study Targeting Hyperinsulinism

Feb 18, 2025, 1:30 AM EST - 8 months ago

Rezolute: Late-Stage Study Targeting Hyperinsulinism


Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day

Nov 17, 2023, 8:00 AM EST - 2 years ago

Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day


Rezolute Reports First Quarter Fiscal 2024 Results

Nov 13, 2023, 4:05 PM EST - 2 years ago

Rezolute Reports First Quarter Fiscal 2024 Results


oaksapollo
oaksapollo Oct. 24 at 1:54 PM
$RZLT open interest on Nov $10 calls is huge, no doubt that’s where we’re headed in the near term.
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 24 at 3:15 AM
$RZLT i was thinking through who may be the most likely acquirer. my guess based on recent bod and mgmt team additions is that it's $RARE. sunil karnawat joined in august 2025 as cco. prior to this, he was an exec at ultragenyx from 2017-2024. erik harris joined the bod in march 2025 and currently serves as cco of ultragenyx. the question i have is how they would structure this deal. ultragenyx doesn't have a lot of cash, but quite a bit of debt. thus, they likely wouldn't be able to do an all-cash deal funded with additional debt. so it would need to likely be cash + stock + contingent payments. i would much rather it be $LLY $NVO $TAK but signs don't point to any of these companies.
1 · Reply
oaksapollo
oaksapollo Oct. 23 at 4:33 PM
$RZLT man what the hell? The stock is now lower than it was prior to the 8K, all gains from yesterday given back and then some. Someone large must be getting out. A bit concerning...
2 · Reply
outlawinvestor1
outlawinvestor1 Oct. 23 at 3:55 PM
$RZLT adding!!!
0 · Reply
marti837
marti837 Oct. 23 at 2:36 PM
$RZLT add
0 · Reply
Zyntax
Zyntax Oct. 23 at 5:20 AM
$RZLT Here’s what I probably could happen if BO price has not yet been set, but I don’t know of course anout the timeframe either. 1. Share price climbs up till X point 2. Outstanding data comes out, we shoot +100% of whatever share price is 3. BO news comes out and we shoot another +100% This would be nice to happen: 1. Share price climbs to $12 before topline data 2. After topline data we are at $24 3. BO news comes out and we are at $48 Not a financial advice. Of course there will be those sellers who sell once topline data comes out and share price jumps
1 · Reply
outlawinvestor1
outlawinvestor1 Oct. 22 at 8:51 PM
$RZLT while previously announced on sept 2 in a pr, the company made the official change to the tumor hi trial record in ct (same day as sec filing - 10/17), further buttoning up loose ends before... 😉 https://clinicaltrials.gov/study/NCT06881992?spons=Rezolute&tab=history&a=5&b=6&compareMode=sideBySide#version-content-panel
0 · Reply
Monty3030
Monty3030 Oct. 22 at 7:56 PM
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Oct. 22 at 7:51 PM
$RZLT Lovely
0 · Reply
SybilDorsett
SybilDorsett Oct. 22 at 7:22 PM
$RZLT Can you imagine where this will go if news comes out AH?
1 · Reply
marti837
marti837 Oct. 22 at 6:54 PM
0 · Reply
Jonita
Jonita Oct. 22 at 6:49 PM
$RZLT in in in
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 22 at 4:08 PM
$RZLT @Night_Owl_Biotech curious of your thoughts on buyout value here? I’ve seen estimated pys between $400 million (one indication) to $1 billion (two indications).
1 · Reply
Monty3030
Monty3030 Oct. 22 at 3:58 PM
$RZLT I just hope it's an all cash offer for a buyout at a specified price per share in advance and none of this so much money upfront and the rest later based on hitting certain milestones.
0 · Reply
Zyntax
Zyntax Oct. 22 at 2:49 PM
$RZLT If BO happens what kind of prices are you guys expecting? I am expecting between $25-$50.
2 · Reply
Monty3030
Monty3030 Oct. 22 at 1:35 PM
0 · Reply
Zyntax
Zyntax Oct. 22 at 12:18 PM
$RZLT Potential M&A on the horizon and the share price staying at these levels 😜.
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 22 at 12:50 AM
$RZLT for those doubting, a company doesn’t upgrade management agreement acceleration clauses + cancel ATMs with Jefferies unless there was a done deal. This isn’t normal house keeping.
1 · Reply
oaksapollo
oaksapollo Oct. 22 at 12:37 AM
$RZLT I really don't believe they would sell the company 6 weeks from pivotal data. I think the change control provisions are just in anticipation of having the option or possibility of selling in the next 6-12 months after the phase 3 reads out. The stock is going to run tomorrow though. The change control coupled with cancelling the ATM is like rocket fuel for the share price!
2 · Reply
lisaparsons
lisaparsons Oct. 21 at 11:17 PM
$RZLT how did presentation go today
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 21 at 9:29 PM
$RZLT the changes to mgmt agreements in the event of change of control. m&a is close.
1 · Reply
SybilDorsett
SybilDorsett Oct. 21 at 9:25 PM
$RZLT and from the 8k "On October 17, 2025, Rezolute, Inc. (the “Company”), Nevan C. Elam, the Company’s Chief Executive Officer, Brian Roberts, the Company’s Chief Medical Officer, Daron Evans, the Company’s Chief Financial Officer and Sunil Karnawat, the Company’s Chief Commercial Officer each entered into amendments to their respective employment agreements to entitle each to a full gross-up payment (the “Gross-up Payment”) for any excise tax and other local, state and federal taxes imposed as a result of any excess parachute payment to be paid in connection with a change of control event as determined under Section 280G of the Internal Revenue Code. The determination of the Gross-Up Payment amount will be made by the Company in its sole discretion. The terms of the respective employment agreements remain unchanged and the amendments will be filed with the Company’s next Quarterly Report on Form 10-Q."
0 · Reply